In preclinical BRAF-mutant melanoma, co-administration of PLX3397 (CSF1R inhibitor) together with PLX4720 (mutant BRAF inhibitor) effectively sensitizes a PD-1-resistant tumor model to anti-PD-1/PD-L1 therapies (23). The gene discussed is CSF1R; the disease is neoplasm.